Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone

•Diabetic kidney disease (DKD) develops in nearly 40% of patients with diabetes, and is a leading cause of end-stage renal disease (ESRD)•Renin-angiotensin-aldosterone system (RAAS) inhibition still remains the cornerstone of treatment of DKD with albuminuria•Finerenone has significantly reduced DKD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes and its complications 2024-05, Vol.38 (5), p.108741-108741, Article 108741
Hauptverfasser:	Filardi, Tiziana, Feraco, Alessandra, Ouvrard-Pascaud, Antoine, Rizzo, Manfredi, Caprio, Massimiliano
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardio-renal-metabolic risk Chronic kidney disease Diabetes Diabetic kidney disease Finerenone Genotype & phenotype Glucose Hyperkalemia Kidney diseases Metabolism Mineralocorticoid receptor Mortality Patients Type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Diabetic kidney disease (DKD) develops in nearly 40% of patients with diabetes, and is a leading cause of end-stage renal disease (ESRD)•Renin-angiotensin-aldosterone system (RAAS) inhibition still remains the cornerstone of treatment of DKD with albuminuria•Finerenone has significantly reduced DKD progression and cardiovascular events compared with placebo in individuals with T2D and advanced DKD in two recent trials, the FIDELIO-DKD and the FIGARO-DKD.•Patients with type-2 diabetes can now benefit of a greater spectrum of therapeutical options to reduce their cardio-renal-metabolic risk.
ISSN:	1056-8727 1873-460X
DOI:	10.1016/j.jdiacomp.2024.108741